RETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy
about
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia BRole of capsid proteins in parvoviruses infectionGene therapy for hemophiliaThe Adeno-Associated Virus Genome Packaging Puzzle.Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors.Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo.The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.Hydrodynamic delivery of Cre protein to lineage-mark or time-stamp mouse hepatocytes in situ.Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challengesUnique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene TransferReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerHigh-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAVThe threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.Adeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological activation of nuclear factor (NF)-κB in muscle of mdx mice.Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.Gambogenic acid inhibits LPS-simulated inflammatory response by suppressing NF-κB and MAPK in macrophages.IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression.Immune responses to AAV vectors: overcoming barriers to successful gene therapyMicroglia-specific targeting by novel capsid-modified AAV6 vectors.Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivoPrimate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis.Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain.Innate Immune Responses to AAV VectorsCellular unfolded protein response against viruses used in gene therapyAerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy.Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.Copackaging of multiple adeno-associated viral vectors in a single production step.AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.Unraveling the complex story of immune responses to AAV vectors trial after trial.Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer.Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells.Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy.
P2860
Q21245486-84164C71-27CC-4DB1-A61A-F203A6D01FAAQ26799552-AA1BF238-5745-48DE-8302-B7F325B364A4Q28081911-18BC89ED-16C8-47FC-B6FD-B0485A1307D6Q33362702-5E0138CF-F057-46C2-98B3-8AF15FFF6EAEQ33881920-96EDD423-508C-4C30-9616-F598FDFBEC3BQ34370111-541C1DD2-8094-4E57-B2FC-2670A21B8A1EQ34548352-509E33B1-F518-4E78-8DE9-6F2FB1A0CE76Q34634722-5BA7B9AA-AE38-45DA-A1EC-C0DC0800D5E2Q34991117-8A99A7C6-116E-4FE1-AE0C-20FC5BE5177FQ35067592-AF69A61D-B0CF-4908-9CF3-21953C71A47BQ35120102-D8C7F448-C5C4-4EDE-94D3-83C75134BB2DQ35431994-5FA341F2-C546-4BA6-8C51-0A52029BAE72Q35561776-447F8670-FCB2-45CA-955A-48B7716AE6CDQ35949356-63111E7B-ABDA-465E-BF67-EC9E7D2C4DF7Q35973549-A91AD9D4-6880-40E1-A966-AE37AFDC90D3Q36085401-0090537A-C68A-40B8-8ED1-2580C5A98159Q36142477-D12E635B-E4D3-4FA0-9295-E56BAF844011Q36155013-140C5412-4C95-46B5-8772-953CBA05BAAFQ36543422-C9A728B6-DB28-4D1D-ADE2-C060AFF2C881Q36621772-75DE6074-144F-41F8-9B80-6BFB236D169BQ36732799-270CD0DB-096B-4812-92A6-44A8C2964939Q36740271-D5C8589C-2155-436D-ABB0-16C9E43D3738Q36760126-76D29919-CFD2-4C04-8232-BB65C70C4F9FQ36954845-323CB5C6-553F-4728-B454-8CBBBE493FB4Q36976498-B437C8D4-BE11-419D-8E6B-67E42547A14DQ36983740-F16FD4C2-6D00-4994-9701-D890434AE69CQ37007749-EBEA2E0A-01DD-44CF-9BAA-49E15267CB6AQ37066326-9AE140BB-8C53-4226-B048-132AA227F3B2Q37331180-6D5F144D-3910-4E0A-B0BE-08B6481316C8Q37910743-6740692A-8054-44B6-B79B-38BE5F065764Q37939843-9B168836-4EAB-494E-AABA-35F2435E1D4CQ38218111-775F4C45-9462-478B-B124-11C64DF81353Q38271253-FAE7159D-58DA-4B7B-88B6-30BB16FF6994Q38860287-AD8D6A4C-3E53-460B-AEAE-583712A6AE3DQ38964154-6F8C3511-CD11-4CA4-A75E-345992A11587Q39136603-7BD3F17B-2C8B-4486-815E-1D5D58107853Q40073271-44E301BA-A5EB-4E84-BAE5-49FCDD749BBFQ40097321-59EA5FE1-EDC8-445A-96BE-15B0012490F5Q40216716-0F41FF9F-4571-4163-931A-240A983F0A41Q40458807-3321F77E-8C2C-4850-B217-543ED0760690
P2860
RETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activation of the NF-kappaB pathway by adeno-associated virus
@nl
RETRACTED: Activation of the N ...... mune response and gene therapy
@ast
RETRACTED: Activation of the N ...... mune response and gene therapy
@en
type
label
Activation of the NF-kappaB pathway by adeno-associated virus
@nl
RETRACTED: Activation of the N ...... mune response and gene therapy
@ast
RETRACTED: Activation of the N ...... mune response and gene therapy
@en
prefLabel
Activation of the NF-kappaB pathway by adeno-associated virus
@nl
RETRACTED: Activation of the N ...... mune response and gene therapy
@ast
RETRACTED: Activation of the N ...... mune response and gene therapy
@en
P2093
P2860
P356
P1476
RETRACTED: Activation of the N ...... mune response and gene therapy
@en
P2093
Arun Srivastava
Ashley T Martino
George Aslanidi
George Q Perrin
Giridhara R Jayandharan
Roland W Herzog
Stephan C Jahn
P2860
P304
P356
10.1073/PNAS.1012753108
P407
P577
2011-02-14T00:00:00Z